How do you choose between neoadjuvant and adjuvant chemo-immunotherapy for patients with resectable stage II-IIIA NSCLC?

Topics: Lung Cancer • Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Indiana University • NCI-CCC Thoracic Tumor Board Question

In light of CheckMate 816 and IMpower010 and FDA approval for neoadjuvant chemo-nivolumab and adjuvant chemo-atezolizumab, how do you decide which systemic therapy/order to offer? Does the shorter duration of immunotherapy with nivolumab play a role in your decision making?

Answer from: Medical Oncologist at Academic Institution

The billion dollar question. For patients with resectable stage II-IIIA NSCLC, how do you choose between neoadjuvant and adjuvant chemo-immunotherapy in light of the recent FDA approval of the CheckMate-816 regimen? Of course, this approval quickly followed in the footsteps of the FDA approval of at...

Comments

Radiation Oncologist at Stroger Hospital
Neoadjuvant chemo and immunotherapy, the CheckMate...

Answer from: Medical Oncologist at Community Practice

Important to keep in mind that we've had no head-to-head comparison of neoadjuvant versus adjuvant immunotherapy, nor has there been an appetite to address this important question thus far. In parsing the existing data, it is important that we remember what we don't know, to avoid extinguishing inte...

Related Questions